These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 27014847)

  • 41. Prodrug and covalent linker strategies for the solubilization of dual-action antioxidants/iron chelators.
    Bebbington D; Dawson CE; Gaur S; Spencer J
    Bioorg Med Chem Lett; 2002 Nov; 12(22):3297-300. PubMed ID: 12392736
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Iron (III)-chelating resins. 3. Synthesis, iron (III)-chelating properties, and in vitro antibacterial activity of compounds containing 3-hydroxy-2-methyl-4(1H)-pyridinone ligands.
    Feng MH; van der Does L; Bantjes A
    J Med Chem; 1993 Sep; 36(19):2822-7. PubMed ID: 8410996
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The hexadentate hydroxypyridinonate TREN-(Me-3,2-HOPO) is a more orally active iron chelator than its bidentate analogue.
    Yokel RA; Fredenburg AM; Durbin PW; Xu J; Rayens MK; Raymond KN
    J Pharm Sci; 2000 Apr; 89(4):545-55. PubMed ID: 10737916
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effects of deferiprone and deferasirox on the structure and function of beta-thalassemia hemoglobin.
    Moosavi-Movahedi AA; Mousavy SJ; Divsalar A; Babaahmadi A; Karimian K; Shafiee A; Kamarie M; Poursasan N; Farzami B; Riazi GH; Hakimelahi GH; Tsai FY; Ahmad F; Amani M; Saboury AA
    J Biomol Struct Dyn; 2009 Dec; 27(3):319-39. PubMed ID: 19795915
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The design of orally active iron chelators.
    Hider RC; Zhou T
    Ann N Y Acad Sci; 2005; 1054():141-54. PubMed ID: 16339660
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Copper complexation by 3-hydroxypyridin-4-one iron chelators: structural and iron competition studies.
    el-Jammal A; Howell PL; Turner MA; Li N; Templeton DM
    J Med Chem; 1994 Feb; 37(4):461-6. PubMed ID: 7509878
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical evaluation of the oral iron chelator deferiprone for the potential treatment of iron overload in bird species.
    Whiteside DP; Barker IK; Mehren KG; Jacobs RM; Conlon PD
    J Zoo Wildl Med; 2004 Mar; 35(1):40-9. PubMed ID: 15193072
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthesis and characterizations of pyridazine-based iron chelators.
    Ma Y; Kong X; Chen YL; Hider RC
    Dalton Trans; 2014 Dec; 43(45):17120-8. PubMed ID: 25311299
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Design and synthesis of fluorinated iron chelators for metabolic study and brain uptake.
    Ma Y; Roy S; Kong X; Chen Y; Liu D; Hider RC
    J Med Chem; 2012 Mar; 55(5):2185-95. PubMed ID: 22339047
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structures of 3-hydroxy-1-(2-methoxyethyl)-2-methyl-4-pyridinone, its hydrochloride and 1-ethyl-3-hydroxy-2-methyl-4-pyridinone hydrochloride hydrate.
    Xiao G; van der Helm D; Goerlitz FH; Hider RC; Dobbin PS
    Acta Crystallogr C; 1993 Sep; 49 ( Pt 9)():1646-9. PubMed ID: 8217022
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Deferiprone: New insight.
    Piga A; Roggero S; Vinciguerra T; Sacchetti L; Gallo V; Longo F
    Ann N Y Acad Sci; 2005; 1054():169-74. PubMed ID: 16339662
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Iron speciation in natural waters by sequential injection analysis with a hexadentate 3-hydroxy-4-pyridinone chelator as chromogenic agent.
    Miranda JL; Mesquita RB; Nunes A; Rangel M; Rangel AO
    Talanta; 2016 Feb; 148():633-40. PubMed ID: 26653494
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis.
    Elalfy M; Wali YA; Qari M; Al Damanhouri G; Al-Tonbary Y; Yazman D; Al Hawsawi Z; Karakas Z; Kilinc Y; Yesilipek MA; Badr M; Elsafy U; Salama M; Abdel Rahman Y; Shebl S; Stilman A; Toiber Temin N; Tricta F
    Pediatr Blood Cancer; 2014 May; 61(5):879-84. PubMed ID: 24376176
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Conjugation to 4-aminoquinoline improves the anti-trypanosomal activity of Deferiprone-type iron chelators.
    Gehrke SS; Pinto EG; Steverding D; Pleban K; Tempone AG; Hider RC; Wagner GK
    Bioorg Med Chem; 2013 Feb; 21(3):805-13. PubMed ID: 23266185
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acyclonucleoside iron chelators of 1-(2-hydroxyethoxy)methyl-2-alkyl-3-hydroxy-4-pyridinones: potential oral iron chelation therapeutics.
    Liu G; Men P; Kenner GH; Miller SC; Bruenger FW
    Nucleosides Nucleotides Nucleic Acids; 2004; 23(3):599-611. PubMed ID: 15113026
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Crystal structures of a new oral iron chelator, 1,2-dimethyl-3-hydroxy-4-pyridone, and its solvates with acetic acid and formic acid.
    Chan HK; Ghosh S; Venkataram S; Rahman YE; Grant DJ
    J Pharm Sci; 1992 Apr; 81(4):353-8. PubMed ID: 1501073
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Deferitazole, a new orally active iron chelator.
    Hider RC; Kong X; Abbate V; Harland R; Conlon K; Luker T
    Dalton Trans; 2015 Mar; 44(11):5197-204. PubMed ID: 25687725
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels.
    Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G
    Int J Clin Pharmacol Ther; 1996 Jul; 34(7):288-92. PubMed ID: 8832304
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chelation of cadmium by combining deferasirox and deferiprone in rats.
    Jamilaldin Fatemi S; Saljooghi AS; Balooch FD; Iranmanesh M; Golbafan MR
    Toxicol Ind Health; 2011 May; 27(4):371-7. PubMed ID: 21245204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.